2002
DOI: 10.2337/diacare.25.3.517
|View full text |Cite
|
Sign up to set email alerts
|

Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes

Abstract: OBJECTIVE -To investigate the dose-response effects of pioglitazone on glycemic control, insulin sensitivity, and insulin secretion in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS-A total of 58 diet-treated patients with type 2 diabetes (aged 54 Ϯ 1 years; 34 men and 24 women; BMI 31.5 Ϯ 0.6 kg/m 2 ) were randomly assigned to receive placebo (n ϭ 11) or 7.5 mg (n ϭ 13), 15 mg (n ϭ 12), 30 mg (n ϭ 11), or 45 mg (n ϭ 11) of pioglitazone per day for 26 weeks. Before and after 26 weeks, subjects unde… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

21
121
1
3

Year Published

2003
2003
2015
2015

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 209 publications
(146 citation statements)
references
References 34 publications
21
121
1
3
Order By: Relevance
“…Various studies have demonstrated the positive effects of glitazones on ␤-cell function (32)(33)(34)(35). In addition, glitazones ameliorate sensitivity of skeletal muscle, adipose tissue, and hepatocytes to circulating insulin.…”
Section: Adverse Effects Of Oral Hypoglycemicmentioning
confidence: 99%
“…Various studies have demonstrated the positive effects of glitazones on ␤-cell function (32)(33)(34)(35). In addition, glitazones ameliorate sensitivity of skeletal muscle, adipose tissue, and hepatocytes to circulating insulin.…”
Section: Adverse Effects Of Oral Hypoglycemicmentioning
confidence: 99%
“…87 Likewise, clinically effective doses of Pioglitazone dose dependently increased body weight. 88 Also, on a longterm basis the TZDs seem to promote weight gain ( Figure 6). Long-term treatment with Pioglitazone monotherapy is accompanied by substantial weight gain, 89 and this weight gain may likely be even higher when provided in combination with sulphonylureas or insulin, and it may be speculated whether this weight gain will increase with continuous treatment.…”
Section: Ppargamma Agonistsfadipogenic Treatment Of Type II Diabetes mentioning
confidence: 99%
“…According to other studies 13,15,16,33) , weight gain was observed in patients with substantial reduction of glycohemoglobin levels following pioglitazone treatment, despite improving insulin resistance. Since obesity is closely related to insulin resistance 34) , these paradoxical effects of pioglitazone could be explained by the context of the distribution of fat mass.…”
Section: Discussionmentioning
confidence: 99%
“…These metabolic abnormalities are a risk factor for cardiovascular diseases, such as coronary heart disease 2,4) . Pioglitazone monotherapy or combination therapy has been demonstrated to improve dyslipidemia, to variable extents, in terms of the modulation of TG and/or HDL-C levels in several clinical trials 13,[15][16][17]24) . In the present study, we evaluated the effects of pioglitazone in comparison with glibenclamide on lipid and glycemic control.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation